Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.

Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M.

Clin Exp Hypertens. 2018 Oct 29:1-8. doi: 10.1080/10641963.2018.1529778. [Epub ahead of print]

PMID:
30373408
2.

Blockade of NKG2D/NKG2D Ligand Interaction Attenuated Cardiac Remodeling after Myocardial Infarction.

Matsumoto K, Obana M, Kobayashi A, Kihara M, Shioi G, Miyagawa S, Maeda M, Sakata Y, Nakayama H, Sawa Y, Fujio Y.

Cardiovasc Res. 2018 Oct 11. doi: 10.1093/cvr/cvy254. [Epub ahead of print]

PMID:
30307485
3.

Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.

Kobayashi K, Toyoda M, Kimura M, Hatori N, Furuki T, Sakai H, Takihata M, Umezono T, Ito S, Suzuki D, Takeda H, Kanamori A, Degawa H, Yamamoto H, Machimura H, Mokubo A, Chin K, Obana M, Hishiki T, Aoyama K, Nakajima S, Umezawa S, Shimura H, Aoyama T, Sato K, Miyakawa M.

Diab Vasc Dis Res. 2018 Oct 4:1479164118802759. doi: 10.1177/1479164118802759. [Epub ahead of print]

PMID:
30284913
4.

[Surgical Experience of Papillary Fibroelastoma Revealed by Cerebral Infarction].

Inoue T, Obana M, Hayashi Y, Yamamoto T.

Kyobu Geka. 2018 Sep;71(9):665-668. Japanese.

PMID:
30185739
5.

Effects of l-Carnitine Supplementation, Botulinum Neurotoxin Injection, and Rehabilitation for a Chronic Stroke Patient.

Endo S, Takahashi T, Sato M, Noya Y, Obana M.

J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3342-3344. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.033. Epub 2018 Sep 1.

PMID:
30181037
6.

2-aminoethoxydiphenyl borate provides an anti-oxidative effect and mediates cardioprotection during ischemia reperfusion in mice.

Morihara H, Obana M, Tanaka S, Kawakatsu I, Tsuchiyama D, Mori S, Suizu H, Ishida A, Kimura R, Tsuchimochi I, Maeda M, Yoshimitsu T, Fujio Y, Nakayama H.

PLoS One. 2017 Dec 21;12(12):e0189948. doi: 10.1371/journal.pone.0189948. eCollection 2017.

7.

Sustained Activation of Guanylate Cyclase-A with TDT, a Natriuretic Peptide Derivative, Exhibits Cardiorenal Protection in Dahl Salt-Sensitive Hypertensive Rats.

Oishi S, Suzuki N, Hasui Y, Homma T, Obana M, Nagayama T, Fujio Y.

J Pharmacol Exp Ther. 2017 Dec;363(3):402-410. doi: 10.1124/jpet.117.244459. Epub 2017 Oct 11.

8.

Protein-Mediated Colloidal Assembly.

Obana M, Silverman BR, Tirrell DA.

J Am Chem Soc. 2017 Oct 11;139(40):14251-14256. doi: 10.1021/jacs.7b07798. Epub 2017 Sep 27.

9.

RORγt-expressing cells attenuate cardiac remodeling after myocardial infarction.

Enomoto D, Matsumoto K, Yamashita T, Kobayashi A, Maeda M, Nakayama H, Obana M, Fujio Y.

PLoS One. 2017 Aug 21;12(8):e0183584. doi: 10.1371/journal.pone.0183584. eCollection 2017.

10.

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2017 Sep;9(9):793-801. doi: 10.14740/jocmr3116w. Epub 2017 Jul 27.

11.

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.

Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2017 Jul;9(7):586-595. doi: 10.14740/jocmr3038w. Epub 2017 May 22.

12.

Adult murine cardiomyocytes exhibit regenerative activity with cell cycle reentry through STAT3 in the healing process of myocarditis.

Miyawaki A, Obana M, Mitsuhara Y, Orimoto A, Nakayasu Y, Yamashita T, Fukada SI, Maeda M, Nakayama H, Fujio Y.

Sci Rep. 2017 May 3;7(1):1407. doi: 10.1038/s41598-017-01426-8.

13.

Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.

Minamitani T, Ma Y, Zhou H, Kida H, Tsai CY, Obana M, Okuzaki D, Fujio Y, Kumanogoh A, Zhao B, Kikutani H, Kieff E, Gewurz BE, Yasui T.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4751-4756. doi: 10.1073/pnas.1701836114. Epub 2017 Mar 28.

14.

Caveolae-specific activation loop between CaMKII and L-type Ca2+ channel aggravates cardiac hypertrophy in α1-adrenergic stimulation.

Tonegawa K, Otsuka W, Kumagai S, Matsunami S, Hayamizu N, Tanaka S, Moriwaki K, Obana M, Maeda M, Asahi M, Kiyonari H, Fujio Y, Nakayama H.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H501-H514. doi: 10.1152/ajpheart.00601.2016. Epub 2016 Dec 30.

15.

Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.

Morihara H, Yamamoto T, Oiwa H, Tonegawa K, Tsuchiyama D, Kawakatsu I, Obana M, Maeda M, Mohri T, Obika S, Fujio Y, Nakayama H.

J Cardiovasc Pharmacol Ther. 2017 May;22(3):273-282. doi: 10.1177/1074248416676392. Epub 2016 Nov 2.

PMID:
27811197
16.

Self-Sorting in the Formation of Metal-Organic Nanotubes: A Crucial Role of 2D Cooperative Interactions.

Obana M, Fukino T, Hikima T, Aida T.

J Am Chem Soc. 2016 Jul 27;138(29):9246-50. doi: 10.1021/jacs.6b04693. Epub 2016 Jul 14.

PMID:
27359046
17.

Moesin is activated in cardiomyocytes in experimental autoimmune myocarditis and mediates cytoskeletal reorganization with protrusion formation.

Miyawaki A, Mitsuhara Y, Orimoto A, Nakayasu Y, Tsunoda S, Obana M, Maeda M, Nakayama H, Yoshioka Y, Tsutsumi Y, Fujio Y.

Am J Physiol Heart Circ Physiol. 2016 Aug 1;311(2):H476-86. doi: 10.1152/ajpheart.00180.2016. Epub 2016 Jun 24.

18.

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.

Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2016 May;8(5):373-8. doi: 10.14740/jocmr2492w. Epub 2016 Mar 20.

19.

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.

Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2016 Mar;8(3):267. doi: 10.14740/jocmr2417wc1. Epub 2016 Jan 26.

20.

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.

Takeda H, Sasai N, Ito S, Obana M, Takuma T, Takai M, Kaneshige H, Machimura H, Kanamori A, Nakajima K, Matsuba I.

J Clin Med Res. 2016 Feb;8(2):130-40. doi: 10.14740/jocmr2418w. Epub 2015 Dec 28.

21.

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.

Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2016 Feb;8(2):116-25. doi: 10.14740/jocmr2417w. Epub 2015 Dec 28. Erratum in: J Clin Med Res. 2016 Mar;8(3):267.

22.

Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction.

Kumagai S, Nakayama H, Fujimoto M, Honda H, Serada S, Ishibashi-Ueda H, Kasai A, Obana M, Sakata Y, Sawa Y, Fujio Y, Naka T.

Cardiovasc Res. 2016 Feb 1;109(2):272-82. doi: 10.1093/cvr/cvv273. Epub 2015 Dec 17.

PMID:
26678356
23.

PROSTATE CANCER SCREENING: PSA TEST AWARENESS AMONG ADULT MALES.

Obana M, O'Lawrence H.

J Health Hum Serv Adm. 2015 Summer;38(1):17-43.

PMID:
26369233
24.

Interleukin-27 induces the endothelial differentiation in Sca-1+ cardiac resident stem cells.

Tanaka T, Obana M, Mohri T, Ebara M, Otani Y, Maeda M, Fujio Y.

Cytokine. 2015 Oct;75(2):365-72. doi: 10.1016/j.cyto.2015.06.009. Epub 2015 Jul 2.

25.

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.

Umezawa S, Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Miyairi Y, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I.

BMC Endocr Disord. 2015 Jul 3;15:34. doi: 10.1186/s12902-015-0033-2.

26.

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.

Ishikawa M, Takai M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I.

J Clin Med Res. 2015 Aug;7(8):607-12. doi: 10.14740/jocmr2149w. Epub 2015 Jun 9.

27.

Cardiac-specific ablation of the STAT3 gene in the subacute phase of myocardial infarction exacerbated cardiac remodeling.

Enomoto D, Obana M, Miyawaki A, Maeda M, Nakayama H, Fujio Y.

Am J Physiol Heart Circ Physiol. 2015 Aug 1;309(3):H471-80. doi: 10.1152/ajpheart.00730.2014. Epub 2015 Jun 8.

28.

Manipulation of discrete nanostructures by selective modulation of noncovalent forces.

Fukino T, Joo H, Hisada Y, Obana M, Yamagishi H, Hikima T, Takata M, Fujita N, Aida T.

Science. 2014 May 2;344(6183):499-504. doi: 10.1126/science.1252120. Epub 2014 Apr 10.

29.

Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?

Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I.

J Clin Med Res. 2014 Apr;6(2):138-44. doi: 10.14740/jocmr1719w. Epub 2014 Feb 6.

30.

Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study.

Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I.

Diabetes Res Clin Pract. 2014 Mar;103(3):e30-3. doi: 10.1016/j.diabres.2013.12.045. Epub 2014 Jan 6.

PMID:
24525293
31.
32.

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.

Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I.

J Diabetes Investig. 2012 Dec 20;3(6):503-9. doi: 10.1111/j.2040-1124.2012.00221.x.

33.

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.

Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amemiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I.

J Clin Med Res. 2012 Oct;4(5):309-13. Epub 2012 Sep 12.

34.

Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart.

Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, Shiragaki M, Kumagai S, Miyawaki A, Takewaki K, Matsumiya G, Maeda M, Yoshiyama M, Nakayama H, Fujio Y.

Am J Physiol Heart Circ Physiol. 2012 Sep 1;303(5):H569-77. doi: 10.1152/ajpheart.00060.2012. Epub 2012 Jun 15.

35.

Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper.

Jin Y, Kanamori A, Ito S, Matoba K, Miyakawa M, Kaneshige H, Obana M, Takai M, Takeda H, Machimura H, Minami N, Kawata T, Honda S, Aoyagi S, Amemiya H, Sasai N, Nakayama M, Naka Y, Terauchi Y, Matsuba I.

J Diabetes Investig. 2012 Jun 6;3(3):252-8. doi: 10.1111/j.2040-1124.2011.00174.x.

36.

Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases.

Fujio Y, Maeda M, Mohri T, Obana M, Iwakura T, Hayama A, Yamashita T, Nakayama H, Azuma J.

J Pharmacol Sci. 2011;117(4):213-22. Epub 2011 Nov 5. Review.

37.

IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.

Yamashita T, Iwakura T, Matsui K, Kawaguchi H, Obana M, Hayama A, Maeda M, Izumi Y, Komuro I, Ohsugi Y, Fujimoto M, Naka T, Kishimoto T, Nakayama H, Fujio Y.

Cardiovasc Res. 2011 Sep 1;91(4):640-8. doi: 10.1093/cvr/cvr148. Epub 2011 May 27.

PMID:
21622681
38.

STAT3/Pim-1 signaling pathway plays a crucial role in endothelial differentiation of cardiac resident Sca-1+ cells both in vitro and in vivo.

Iwakura T, Mohri T, Hamatani T, Obana M, Yamashita T, Maeda M, Katakami N, Kaneto H, Oka T, Komuro I, Azuma J, Nakayama H, Fujio Y.

J Mol Cell Cardiol. 2011 Aug;51(2):207-14. doi: 10.1016/j.yjmcc.2011.04.013. Epub 2011 May 6.

PMID:
21600215
39.

Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction.

Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, Nakaoka Y, Komuro I, Takeda K, Matsumiya G, Azuma J, Fujio Y.

Circulation. 2010 Feb 9;121(5):684-91. doi: 10.1161/CIRCULATIONAHA.109.893677. Epub 2010 Jan 25.

PMID:
20100971
40.

Branch segment occlusion with acute myocardial infarction is a risk for left ventricular free wall rupture.

Ino Y, Kubo T, Tomobuchi Y, Oshika H, Kitabata H, Obana M, Tanimoto T, Takarada S, Tanaka A, Imanishi T, Okamura Y, Akasaka T.

Circ J. 2009 Aug;73(8):1473-8. Epub 2009 Jun 30.

41.

Signals through glycoprotein 130 regulate the endothelial differentiation of cardiac stem cells.

Mohri T, Fujio Y, Obana M, Iwakura T, Matsuda K, Maeda M, Azuma J.

Arterioscler Thromb Vasc Biol. 2009 May;29(5):754-60. doi: 10.1161/ATVBAHA.108.174870. Epub 2009 Feb 12.

PMID:
19213943
42.

Increased chymase-positive mast cells in children with crescentic glomerulonephritis.

Togawa H, Nakanishi K, Shima Y, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N.

Pediatr Nephrol. 2009 May;24(5):1071-5. doi: 10.1007/s00467-008-1044-2. Epub 2008 Dec 3.

PMID:
19050935
43.

Membranous nephropathy associated with thyroid-peroxidase antigen.

Shima Y, Nakanishi K, Togawa H, Obana M, Sako M, Miyawaki M, Nozu K, Iijima K, Yoshikawa N.

Pediatr Nephrol. 2009 Mar;24(3):605-8. doi: 10.1007/s00467-008-0973-0. Epub 2008 Sep 2.

PMID:
18762990
44.

Connective tissue growth factor induces cardiac hypertrophy through Akt signaling.

Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J.

Biochem Biophys Res Commun. 2008 May 30;370(2):274-8. doi: 10.1016/j.bbrc.2008.03.100. Epub 2008 Mar 28.

PMID:
18375200
45.

Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes.

Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, Azuma J.

Cardiovasc Res. 2008 Jul 1;79(1):89-96. doi: 10.1093/cvr/cvn076. Epub 2008 Mar 17.

PMID:
18346979
46.

Improved renal survival in Japanese children with IgA nephropathy.

Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N.

Pediatr Nephrol. 2008 Jun;23(6):905-12. doi: 10.1007/s00467-007-0726-5.

47.

Segmental membranous glomerulonephritis in children: comparison with global membranous glomerulonephritis.

Obana M, Nakanishi K, Sako M, Yata N, Nozu K, Tanaka R, Iijima K, Yoshikawa N.

Clin J Am Soc Nephrol. 2006 Jul;1(4):723-9. Epub 2006 Apr 26.

48.

Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine.

Kimura R, Maeda M, Arita A, Oshima Y, Obana M, Ito T, Yamamoto Y, Mohri T, Kishimoto T, Kawase I, Fujio Y, Azuma J.

Cytokine. 2007 May;38(2):107-15. Epub 2007 Jul 16.

PMID:
17629706
49.

Hyperglycemia accelerated endothelial progenitor cell senescence via the activation of p38 mitogen-activated protein kinase.

Kuki S, Imanishi T, Kobayashi K, Matsuo Y, Obana M, Akasaka T.

Circ J. 2006 Aug;70(8):1076-81.

50.

Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome.

Sako M, Nakanishi K, Obana M, Yata N, Hoshii S, Takahashi S, Wada N, Takahashi Y, Kaku Y, Satomura K, Ikeda M, Honda M, Iijima K, Yoshikawa N.

Kidney Int. 2005 Apr;67(4):1248-55.

Supplemental Content

Support Center